Racial Disparities in Intravenous Recombinant Tissue Plasminogen Activator Use Persist at Primary Stroke Centers

被引:51
|
作者
Aparicio, Hugo J. [1 ,2 ]
Carr, Brendan G. [5 ]
Kasner, Scott E. [2 ]
Kallan, Michael J. [3 ]
Albright, Karen C. [6 ,7 ,8 ]
Kleindorfer, Dawn O. [9 ]
Mullen, Michael T. [2 ,4 ]
机构
[1] Boston Univ, Dept Neurol, Boston, MA 02215 USA
[2] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA
[3] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[4] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA
[5] Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19107 USA
[6] Univ Alabama Birmingham, Hlth Serv & Outcomes Res Ctr Outcome & Effectiven, Birmingham, AL USA
[7] Univ Alabama Birmingham, Ctr Excellence Comparat Effectiveness Res Elimina, Minor Hlth & Hlth Dispar Res Ctr, Birmingham, AL USA
[8] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA
[9] Univ Cincinnati, Dept Neurol, Cincinnati, OH 45221 USA
来源
基金
美国医疗保健研究与质量局; 美国国家卫生研究院;
关键词
health disparities; health policy; stroke; stroke care; thrombolysis; ACUTE ISCHEMIC-STROKE; CERTIFIED PRIMARY STROKE; AMERICAN-HEART-ASSOCIATION; MEDICAL-SERVICES USE; ETHNIC DISPARITIES; TEMPORAL TRENDS; UNITED-STATES; RISK-FACTORS; OUTCOMES; EMERGENCY;
D O I
10.1161/JAHA.115.001877
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Primary stroke centers (PSCs) utilize more recombinant tissue plasminogen activator (rt-PA) than non-PSCs. The impact of PSCs on racial disparities in rt-PA use is unknown. Methods and Results-We used data from the Nationwide Inpatient Sample from 2004 to 2010, limited to states that publicly reported hospital identity and race. Hospitals certified as PSCs by The Joint Commission were identified. Adults with a diagnosis of ischemic stroke were analyzed. Rt-PA use was defined by the International Classification of Diseases, 9th Revision procedure code 99.10. Discharges (304 152 patients) from 26 states met eligibility criteria, and of these 71.5% were white, 15.0% black, 7.9% Hispanic, and 5.6% other. Overall, 24.7% of white, 27.4% of black, 16.2% of Hispanic, and 29.8% of other patients presented to PSCs. A higher proportion received rt-PA at PSCs than non-PSCs in all race/ethnic groups (white 7.6% versus 2.6%, black 4.8% versus 2.0%, Hispanic 7.1% versus 2.4%, other 7.2% versus 2.5%, all P<0.001). In a multivariable model adjusting for year, age, sex, insurance, medical comorbidities, a diagnosis-related group-based mortality risk indicator, ZIP code median income, and hospital characteristics, blacks were less likely to receive rt-PA than whites at non-PSCs (odds ratio=0.58, 95% CI 0.50 to 0.67) and PSCs (odds ratio=0.63, 95% CI 0.54 to 0.74) and Hispanics were less likely than whites to receive rt-PA at PSCs (odds ratio=0.77, 95% CI: 0.63 to 0.95). In the fully adjusted model, interaction between race and presentation to a PSC for likelihood of receiving rt-PA did not reach significance (P=0.98). Conclusions-Racial disparities in intravenous rt-PA use were not reduced by presentation to PSCs. Black patients were less likely to receive thrombolytic treatment than white patients at both non-PSCs and PSCs. Hispanic patients were less likely to be seen at PSCs relative to white patients and were less likely to receive intravenous rt-PA in the fully adjusted model.
引用
下载
收藏
页数:11
相关论文
共 50 条
  • [21] Very Early Mobilization in Stroke Patients Treated with Intravenous Recombinant Tissue Plasminogen Activator
    Arnold, Scott M.
    Dinkins, Maryane
    Mooney, Lesia H.
    Freeman, William D.
    Rawal, Bhupendra
    Heckman, Michael G.
    Davis, Olivia A.
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2015, 24 (06): : 1168 - 1173
  • [22] Quantitative electroencephalograph in acute ischemic stroke treated with intravenous recombinant tissue plasminogen activator
    Yang, Juan
    Zhao, Xiaohui
    Bai, Qingke
    Zhao, Zhengguo
    Sui, Haijing
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (01): : 507 - 514
  • [23] Trends in the use of intravenous recombinant tissue plasminogen activator from northwest India
    Pandian, Jeyaraj D.
    Bhullar, Ranjeet Singh
    Kaur, Parmdeep
    Dhillon, Sudeepa
    Toor, Gagan
    Singh, Yashpal
    INTERNATIONAL JOURNAL OF STROKE, 2012, 7 (04) : 363 - 364
  • [24] Racial Disparities in Tissue Plasminogen Activator Treatment Rate for Stroke A Population-Based Study
    Hsia, Amie W.
    Edwards, Dorothy F.
    Morgenstern, Lewis B.
    Wing, Jeffrey J.
    Brown, Nina C.
    Coles, Regina
    Loftin, Sarah
    Wein, Andrea
    Koslosky, Sara S.
    Fatima, Sabiha
    Sanchez, Brisa N.
    Fokar, Ali
    Gibbons, M. Chris
    Shara, Nawar
    Jayam-Trouth, Annapurni
    Kidwell, Chelsea S.
    STROKE, 2011, 42 (08) : 2217 - 2221
  • [25] Use of Recombinant Tissue Plasminogen Activator (rTPA) in Cancer Patients with Acute Stroke
    Graber, Jerome J.
    Nayak, Lakshmi
    DeAngelis, Lisa M.
    NEUROLOGY, 2011, 76 (09) : A634 - A635
  • [26] Recombinant tissue plasminogen activator for acute ischemic stroke
    Al-Buhairi, AR
    Jan, MM
    SAUDI MEDICAL JOURNAL, 2002, 23 (01) : 13 - 19
  • [27] Informed Consent for Intravenous Tissue Plasminogen Activator in New York State Designated Stroke Centers
    Weintraub, Michael I.
    Colello, Anna D.
    Johnson, Samantha A.
    McClellan, Fabienne
    Cole, Steven P.
    Benesch, Curtis
    Rudolph, Steven H.
    Levine, Steven R.
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2017, 26 (06): : 1274 - 1279
  • [28] Intravenous thrombolysis for acute ischaemic stroke: Preliminary experience with recombinant tissue plasminogen activator in the UK
    Walters, MR
    Muir, KW
    Harbison, J
    Lees, KR
    Ford, GA
    CEREBROVASCULAR DISEASES, 2005, 20 (06) : 438 - 442
  • [29] An ischemic stroke during intravenous recombinant tissue plasminogen activator infusion for evolving myocardial infarction
    Chang, GYN
    EUROPEAN JOURNAL OF NEUROLOGY, 2001, 8 (03) : 267 - 268
  • [30] Predictors of Intracerebral Hemorrhage in Acute Stroke Patients Receiving Intravenous Recombinant Tissue Plasminogen Activator
    Chenna, Vijay
    Kaul, Subhash
    Tandra, Swetha
    Yareeda, Sireesha
    Mathukumalli, Neeharika
    Kohat, Abhijeet Kumar
    Kandadai, Rukmini Mridula
    Turaga, Suryaprabha
    Sheik, Jabeen Afshan
    Meena, A. K.
    Borgohain, Rupam
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2018, 21 (03) : 214 - 219